BioXcel Therapeutics (BTAIQ) Long-Term Debt Repayments (2026)
BioXcel Therapeutics' Long-Term Debt Repayments was $304,000 in Q2 2026, down 96.3% from the prior quarter.
Powered by 
Analysis
BioXcel Therapeutics (BTAIQ) Long-Term Debt Repayments (2026) Analysis & Trends
On a trailing twelve-month basis, BioXcel Therapeutics' Long-Term Debt Repayments was $8.41 million through Jun 30, 2026; for FY2024, it was $2.5 million.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | LT Debt Repayment (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 1.00 Mn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 2.00 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 5.00 Mn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | -2.45 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 17.00 Mn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | - |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | - |
| 10 | BioXcel Therapeutics | 1.57 Mn | 1.57 Mn | 160,000.00 | 304,000.00 |
API Access
BioXcel Therapeutics Long-Term Debt Repayments API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=BTAIQ&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "long-term-debt-repayments", "ticker": "BTAIQ", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=BTAIQ&period=max&api_key=YOUR_API_KEY");
const data = await res.json();